NDLI: Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma

Content Provider	Springer Nature : BioMed Central
Author	Zhang, Lina Zhang, Run Wang, Jing Chen, Ying Qiao, Chun Shi, Qinglin Jin, Yuanyuan Shen, Xuxing Li, Jianyong Chen, Lijuan
Abstract	Background With the rapid development of next-generation sequencing (NGS) technologies, researchers are making efforts to reveal the genomic landscape of multiple myeloma (MM). However, the clinical significance of many mutations remains poorly defined due to the genetic heterogeneity of MM. To systematically explore the clinical implications of gene mutations and build practical prognostic models, we performed DNA sequencing in newly diagnosed MM patients. Methods MM cells were purified from bone marrow aspirates using CD138 microbeads and subjected to sequencing with a 387-gene Panel. Nomogram was developed using Cox’s proportional hazards model, and candidate variables were screened by stepwise regression. Internal validation was carried out by the bootstrap method. Results Between July 2016 and December 2020, a total of 147 patients were included in our study. We found patients with a higher mutational load had a significantly shorter progress-free survival (PFS) (19.0 vs. 32.0 months, P = 0.0098) and overall survival (OS) (3-year OS rates were 66.1% and 80.0%, P = 0.0290). Mutations in chromatin regulators (CRs) including KMT2C (14.3%), KMT2D (14.3%), EP300 (11.6%) and ARID gene family (31.3%) were highly frequent in newly diagnosed MM patients. Interestingly, proteins encoded by these genes could form a complex called KMT2C/D COMPASS (KCDCOMs). Patients with mutations of ARID gene family had a significantly shorter PFS (15.5 vs. 34.0 months, P = 0.0003) and OS (3-year OS rates were 64.9% and 81.0%, P = 0.0351) than patients without ARID gene mutations. Incorporating ARID gene mutations into the current staging system could successfully improve their prognostic performance. The PFS and OS nomogram models (including 1q21 copies, ARID gene mutations, extramedullary disease, mutational load and TP53 mutations) showed good predicting performance in both training and validation sets. Conclusion Our findings emphasized the importance of CRs mutations in newly diagnosed MM patients and indicated the mutations affecting KCDCOMs might promote the development of MM. High mutational load and harboring mutations in the ARID gene family were novel predictors of adverse prognosis in MM. Prognostic models based on gene mutations were commendably prognostic evaluation methods that could provide a reference for clinical practices.
Related Links	https://clinicalepigeneticsjournal.biomedcentral.com/counter/pdf/10.1186/s13148-022-01314-7.pdf
Ending Page	12
Page Count	12
Starting Page	1
File Format	HTM / HTML
ISSN	18687083
DOI	10.1186/s13148-022-01314-7
Journal	Clinical Epigenetics
Issue Number	1
Volume Number	14
Language	English
Publisher	BioMed Central
Publisher Date	2022-07-23
Access Restriction	Open
Subject Keyword	Human Genetics Gene Function Next-generation sequencing Chromatin regulator Epigenetic Multiple myeloma Nomogram
Content Type	Text
Resource Type	Article
Subject	Molecular Biology Genetics (clinical) Developmental Biology Genetics
Journal Impact Factor	4.8/2023
5-Year Journal Impact Factor	5.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Chromatin accessibility analysis identifies GSTM1 as a prognostic marker in human glioblastoma patients

Estimating breast tissue-specific DNA methylation age using next-generation sequencing data

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact

Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells

SMYD3: a regulator of epigenetic and signaling pathways in cancer

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

Next-generation sequencing methylation profiling of subjects with obesity identifies novel gene changes

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses

Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma

Similar Documents

Chromatin accessibility analysis identifies GSTM1 as a prognostic marker in human glioblastoma patients

Estimating breast tissue-specific DNA methylation age using next-generation sequencing data

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact

Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells

SMYD3: a regulator of epigenetic and signaling pathways in cancer

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

Next-generation sequencing methylation profiling of subjects with obesity identifies novel gene changes

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses

Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma